Quest Diagnostics Reaches New 52-Week High of $214.15

Quest Diagnostics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 214.15 on June 30, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 49.82%, significantly outpacing the S&P 500's growth of 20.86% during the same period. As a mid-cap company with a market capitalization of USD 31,451 million, Quest Diagnostics operates within the miscellaneous industry. The stock's price-to-earnings (P/E) ratio stands at 28.00, reflecting its valuation in the market. Additionally, the company boasts a robust dividend yield of 29.40%, indicating a strong return for shareholders. Financial metrics further highlight Quest Diagnostics' solid position, with a debt-to-equity ratio of 0.75 and a return on equity of 15.54%. The price-to-book ratio is recorded at 4.39, providing insight into the company's valuation relative to its assets. The stock's previous 52-week low was USD 164.65, marking a significant upward trend in its performance.